Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;46(4):887-894.
doi: 10.1111/jcpt.13461. Epub 2021 Jun 7.

Albumin for cirrhosis-related complications

Brian L Erstad  1
Affiliations
Review

Albumin for cirrhosis-related complications

Brian L Erstad. J Clin Pharm Ther. 2021 Aug.

Abstract

What is known and objective: The purpose of this paper was to discuss the limitations of the studies serving as the evidence for recommendations in clinical practice guidelines concerning albumin use for cirrhosis-related complications, review relevant studies published since the guidelines and suggest directions for future investigations.

Comment: There are no recent comprehensive clinical practice guidelines concerning albumin. Instead, more recent albumin guidelines reflect areas of specialty practice such as those by American and European associations for the study of the liver and liver disease. Studies published since the guidelines are useful for helping to define the most appropriate indications for albumin with respect to cirrhosis-related complications, as well as directions for future research.

What is new and conclusion: Albumin has a long history of attempts to define appropriate uses by meta-analysis, but given the high cost and episodic shortages of albumin, there is a need for adequately powered randomized controlled trials using current state-of-the-art care evaluating the use of albumin to prevent or treat cirrhosis-related complications.

Keywords: albumin; cirrhosis; hepatorenal syndrome; large-volume paracentesis; spontaneous bacterial peritonitis.

PubMed Disclaimer

References

REFERENCES

    1. Buckley MS, Knutson KD, Agarwal SK, et al. Clinical pharmacist-led impact on inappropriate albumin use and costs in the critically ill. Ann Pharmacother. 2020;54(2):105-112. https://doi.org/10.1177/1060028019877471
    1. Buckley MS, Agarwal SK, Lansburg JM, Kopp BJ, Erstad BL. Clinical pharmacist-led impact on inappropriate albumin utilization and associated costs in general ward patients. Ann Pharmacother. 2021;55(1):44-51. https://doi.org/10.1177/1060028020935575
    1. Janeway CA, Gibson ST, Woodruff LM, Heyl JT, Bailey OT, Newhouser LR. Chemical, clinical, and immunological studies on the products of human plasma fractionation. VII. concentrated human serum albumin. J Clin Invest. 1944;23(4):465-490. https://doi.org/10.1172/JCI101514
    1. Patek AJ, Mankin H, Colcher H, Lowell A, Earle DP. The effects of intravenous injection of concentrated human serum albumin upon blood plasma, ascites and renal functions in three patients with cirrhosis of the liver. J Clin Invest. 1948;27(1):135-144. https://doi.org/10.1172/JCI101916. PMID: 16695524; PMCID: PMC439482.
    1. Wilkinson P, Sherlock S. The effect of repeated albumin infusions in patients with cirrhosis. Lancet. 1962;280(7266):1125-1129. https://doi.org/10.1016/S0140-6736(62)90895-4

LinkOut - more resources